UNSPSC 51111874: Tamoxifen citrate

This classification denotes a selective estrogen receptor modulator and protein kinase c inhibitor with the molecular formula C26H29NO.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7FRV7310N6. European Medicines Agency schedules tamoxifen citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04672MIG. The term tamoxifen citrate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule tamoxifen citrate under HS 29221990 and SITC 51461.

As of Q4 2014, TAMOXIFEN CITRATE remains US FDA's Preferred Term for this commodity. Tamoxifen citrate bears US NLM identifiers UMLS ID C0919390 and NCI Concept Code C855. SMILES: CC/C(=C(\C1CCCCC1)/C2CCC(CC2)OCCN(C)C)/C3CCCCC3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.

UNSPSC 51111874 Tamoxifen citrate, a Commodity code, covers generic pharmaceutical active ingredients and finished dosage forms procured by state and local health systems, correctional facilities, and cooperative purchasing alliances for disease treatment and prevention. State and local governments buy this code as part of broader pharmaceutical supply agreements with manufacturers and authorized wholesalers, typically specifying National Drug Codes (NDCs), packaging configurations, and pricing structures tied to competitive benchmarks or wholesale acquisition cost (WAC). Issuing bodies include state departments of administration and health, counties, municipalities, and special-purpose purchasing cooperatives that aggregate demand across multiple jurisdictions to achieve volume discounts and standardized pricing. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is a repeat buyer consolidating procurement for participating states and local facilities.

MMCAP issued a Request for Proposal (S1070000015802) on January 20, 2026 to establish multiple contracts for generic pharmaceuticals and over-the-counter products with response due March 26, 2026. The procurement requires vendors to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health, and Morris & Dickson Co., LLC), maintain current Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance, and offer pricing in formats including flat price, net price (NF30, NF60, NF90), or WAC-minus structures. Evaluation is weighted 75 percent on price competitiveness, with 10 percent on fixed pricing for contract term, 5 percent each on administrative fee data format compliance, EDI capability, and acceptance of a 3 percent administrative fee. The contract term runs two years effective July 1, 2026 for new vendors, with optional extensions at MMCAP's discretion. Vendors must carry $5 million commercial general liability insurance, $2 million network security and privacy liability, and $2 million professional liability, with performance penalties of $200 to $1,500 per violation. Participation spans Minnesota and Oregon among identified jurisdictions.